View Future GrowthGlow Lifetech 과거 순이익 실적과거 기준 점검 0/6Glow Lifetech은 연평균 49.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 30.5%의 비율로 증가했습니다. 매출은 연평균 82%의 비율로 증가했습니다.핵심 정보49.62%순이익 성장률63.09%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률23.06%매출 성장률82.00%자기자본이익률-16.56%순이익률-23.85%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 26First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$643.5k (up 35% from 1Q 2025). Net loss: CA$58.9k (loss narrowed 60% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 08Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.03 loss in FY 2024)Full year 2025 results: CA$0.004 loss per share (improved from CA$0.03 loss in FY 2024). Revenue: CA$2.05m (up 146% from FY 2024). Net loss: CA$617.9k (loss narrowed 77% from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$630.8k (up 178% from 3Q 2024). Net loss: CA$106.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 28Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2024)Second quarter 2025 results: CA$0.002 loss per share. Revenue: CA$436.3k (up 186% from 2Q 2024). Net loss: CA$368.6k (loss widened 42% from 2Q 2024).Reported Earnings • May 07Full year 2024 earnings released: CA$0.03 loss per share (vs CA$0.029 loss in FY 2023)Full year 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.029 loss in FY 2023). Revenue: CA$836.2k (up CA$792.3k from FY 2023). Net loss: CA$2.66m (loss widened 62% from FY 2023). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesReported Earnings • May 26First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$643.5k (up 35% from 1Q 2025). Net loss: CA$58.9k (loss narrowed 60% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$9.62m market cap, or US$7.06m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$2.1m revenue, or US$1.5m).Reported Earnings • Apr 08Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.03 loss in FY 2024)Full year 2025 results: CA$0.004 loss per share (improved from CA$0.03 loss in FY 2024). Revenue: CA$2.05m (up 146% from FY 2024). Net loss: CA$617.9k (loss narrowed 77% from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Recent Insider Transactions Derivative • Mar 29CEO & Director exercised options to buy CA$66k worth of stock.On the 23rd of March, Roberto Carducci exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$60k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since June 2025, Roberto's direct individual holding has increased from 6.88m shares to 8.08m. Company insiders have collectively bought CA$141k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions Derivative • Mar 21CFO & Corporate Secretary exercised options to buy CA$66k worth of stock.On the 17th of March, Joshua Bald exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$66k. This transaction amounted to 56% of their direct individual holding at the time of the trade. Since June 2025, Joshua's direct individual holding has increased from 1.66m shares to 2.34m. This was the only transaction from an insider over the last 12 months.공고 • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$630.8k (up 178% from 3Q 2024). Net loss: CA$106.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (CA$8.57m market cap, or US$6.11m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$1.5m revenue, or US$1.0m).Reported Earnings • Aug 28Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2024)Second quarter 2025 results: CA$0.002 loss per share. Revenue: CA$436.3k (up 186% from 2Q 2024). Net loss: CA$368.6k (loss widened 42% from 2Q 2024).공고 • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.공고 • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.Reported Earnings • May 07Full year 2024 earnings released: CA$0.03 loss per share (vs CA$0.029 loss in FY 2023)Full year 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.029 loss in FY 2023). Revenue: CA$836.2k (up CA$792.3k from FY 2023). Net loss: CA$2.66m (loss widened 62% from FY 2023). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공고 • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.공고 • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities lawsNew Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (91% average weekly change). Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (CA$6.68m market cap, or US$4.95m).공고 • Sep 25Glow Lifetech Corp. announced that it has received CAD 1.2 million in fundingOn September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering.공고 • Aug 14Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in fundingGlow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.Board Change • Aug 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 21Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). ,CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Apr 17Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in fundingGlow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (42% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (CA$1.84m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding).공고 • Dec 17Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in fundingGlow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.공고 • Sep 08Glow Lifetech Corp. Appoints Daniel Proska to Its Board of DirectorsGlow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023.공고 • Jul 07Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder TechnologyGlow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products.공고 • Dec 09Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Nov 03Glow Lifetech Corp. Completes Development of Proprietary MyCell Liquid Cannabis Ingredients; Advances Plans to Launch in Canadian MarketGlow LifeTech Corp. announced the completion of development of its proprietary MyCell® liquid cannabis ingredients, including THC and CBD. The Company now plans for commercialization in the Canadian market, given product readiness. The successful development of MyCell® liquid water-soluble THC and CBD ingredients allows the Company to immediately progress towards scaling-up production and making preparations for sellinginto the well-established market for THC and CBD products in Canada, as the first step in its global commercial strategy. As many cannabis industry players currently struggle with low-margin, commoditized product offerings, Glow has always maintained a long-term focus on delivering differentiated, value-added products and building a platform for high-margin growth. With its portfolio of high-performance, technology-driven products, the Company is well-positioned to capitalize on the growing industry-wide evolution towards high-value, science-based products. Glow's MyCell® Technology is a cutting-edge delivery system that optimizes the absorption, bioavailability and effectiveness of several verticals of natural active compounds including cannabinoids, vitamins, and botanicals, using only 100% natural components. It transforms poorly absorbed natural compounds, such as THC and CBD, into water-soluble compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its flexible technology platform and robust portfolio of enhanced ingredients, Glow can power a variety of product formats including: droppers, sprays, beverages, gummies, foods, topicals, and more. The Company has prudently built an efficient, asset-light cannabis production operation with a factor-in-factory manufacturing partnership in Toronto, Canada, that is designed to scale and minimize costs. With the processing facility built and equipment commissioned in early 2022, it will house all of Glow's cannabis-related R&D activities, serving as the Company's cannabis production centre of excellence to develop technologies and products that can be scaled globally. This single licensed production location provides the Company the necessary production capacity to produce a diverse portfolio of cannabis products to service the Canadian market nationally, across both adult-use and medical cannabis markets.공고 • Jul 19Glow Lifetech Reports Positive Preliminary Results from Clinical Study of Artemic Support(R) on Patients with Long Covid SyndromeGlow LifeTech Corp. reported positive preliminary results from a clinical study into the influence of ArtemiC Support® on patients with Post-Acute COVID Syndrome, also known as Long COVID. Long COVID refers to the ongoing health problems that people can experience four or more weeks after being infected with SARS-COV-2[2], the virus responsible for COVID-19. Long COVID is believed to affect more than 50% of all COVID-19 patients. The study, undertaken in conjunction with primary care clinicals in Barcelona, CAP Can Bou and Sardenya EAP Spain, was an open label, single arm study, consisting of six-weeks of treatment with ArtemiC Support®. The objectives of the study were to provide an initial assessment of the safety and efficacy of ArtemiC Support® in Long COVID patients. The clinical study was sponsored by Swiss PharmaCan AG and co-sponsored by Glow and MGC Pharmaceuticals Ltd. The study enrolled 150 patients suffering from Long COVID who were administered ArtemiC Support®, under the supervision of their doctor, with their progress being measured using a Post-COVID Functional Scale (PCFS) and symptoms on a 10-point Likert scale at 1, 2, 3 and 6 weeks after treatment initiation. Symptoms measured include: Dyspnea - shortness of breath Asthenia - abnormal physical weakness or lack of energy, Anosmia - loss of senses of smell, Ageusia - loss of sense of taste, Cough, Headache, Mental confusion. The results of the study demonstrated a statistically significant reduction in the severity of several Long COVID symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion over the course of the protocol. The graphs below show the Emmeans (Estimated Marginal Mean) observed results from data collected during the Artemic Support® Long COVID study: · Dyspnea: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 5), with a higher emmean indicating higher severity and a lower enmean indicating a lower severity. · Cough: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visits 4 & 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. · Asthenia: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. Headache: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower enmeans indicating a lower. Mental confusion: a significant difference was seen in reported symptom intensity (visit 1 to visit 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity.공고 • Jul 09Glow Lifetech Corp. Provides an Update on Commercial Operations, Cannabis-Related Development Activities and Clinical Studies Related to Its Proprietary Mycell®-Enhanced ProductsGlow Lifetech Corp. provided an update on commercial operations, cannabis-related development activities and clinical studies related to its proprietary MyCell®-enhanced products. Glow is now focused on the final stages of development of proprietary CBD (cannabidiol) and THC1 (tetrahydrocannabinol) water-soluble ingredients in preparation for launch in Canada. With Glow's licensed cannabis processing space now built out and equipment successfully commissioned earlier this year, the company has been actively developing a diverse portfolio of high-bioavailability cannabis ingredients and new proprietary technologies to expand the Company's portfolio of solutions. The Company's MyCell® Technology is an advanced delivery system that transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high- absorption and precise dosing. Glow is engaged with a renowned branding firm and is in the late stages of establishing a refreshed brand identity that reflects the cutting-edge performance and quality of its technology and products. The Company is also pleased to report the completion of the recruitment phase of the ongoing clinical study on patients with long COVID syndrome, to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology.2 Glow's portfolio of high-performance water-soluble cannabis ingredient solutions will unlock a step- change in what's possible with cannabis-infused products, enabling partner brands to easily innovate and differentiate with high-value products that are more effective, fast-acting, consistent and deliver predictable dosing. The versatility of MyCell® enhanced concentrates allows them to power a variety of product formats including: droppers, beverages, foods, topicals, and capsules.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Dec 27Glow LifeTech Corp Announces Commencement of Clinical Study of Artemic Support Featuring Mycell Technology on Patients with Long COVIDGlow LifeTech Corp. announced that it is co-sponsoring a clinical study to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology, in patients with Long COVID syndrome. Post-acute COVID syndrome (PACS) or "Long COVID" presents itself as a wide range of ongoing symptoms patients can experience for four or more weeks after first being infected with SARS-COV-2[1]. Long Covid is estimated to affect approximately 10%-35% of all COVID patients[2], and the inflammatory response is generally thought to be fundamental to the persistence of symptoms. Therefore, the ability to reduce inflammation could improve patient outcomes, and this study is aimed at validating such a framework for Artemic Support®. Artemic Support® is a natural health product made from curcumin, boswellia and vitamin C designed to reduce inflammatory responses and is formulated with MyCell® Technology ingredients to increase bioavailability and deliver faster, more effective cellular absorption of natural active ingredients. This new innovation is the second product in the Company's Artemic product range to progress to the Clinical Trial phase to determine safety and efficacy against SARS2-COV-2 related diseases. In April 2020, the Company announced it submitted its first product, ArtemicTM Rescue, to Health Canada as a Natural Health Product following successful results from a Phase II Clinical Trial with patients diagnosed with moderate COVID-19.공고 • Apr 29Glow Lifetech Corp. Submits Application to Health Canada to Obtain Product Licenses for Artemic™MGC Pharmaceuticals Ltd. announced that Glow LifeTech has submitted an application to Health Canada to obtain product licenses for ArtemiC™ as a Natural Health Product (NHP), per its CSE announcement on 27 April 2021. As announced on 15 December 2020, MGC Pharma released the results of a successful Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing for toxicity and mechanism of action. ArtemiC™ was submitted to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) on March 11, 2021. The application, which is currently under review by Health Canada, included ArtemiC™ supporting COVID-19 Phase II clinical trial results. Under Canadian regulations, all NHPs must obtain premarket approval by Health Canada to assure they are safe, effective and of high quality before being allowed to be sold in Canada. Once Health Canada makes this assessment, they are issued a National Product Number (NPN). Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Caribbean countries as a food supplement. ArtemiC™ is a clinically tested oral spray containing four natural active ingredients: Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses the MyCell™ delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC™ was a collaborative development effort between MGC Pharma, Swiss PharmaCan AG and Glow, and is manufactured by MGC Pharma.매출 및 비용 세부 내역Glow Lifetech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이CNSX:GLOW 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Mar 262-12031 Dec 252-12030 Sep 252-22030 Jun 251-32031 Mar 251-32031 Dec 241-32030 Sep 241-11030 Jun 240-11031 Mar 240-11031 Dec 230-21030 Sep 230-21030 Jun 230-21031 Mar 230-21031 Dec 220-21030 Sep 220-11030 Jun 220-11031 Mar 220-22031 Dec 210-115030 Sep 210-125030 Jun 210-135031 Mar 210-124031 Dec 200-11030 Sep 200-21030 Jun 200-11031 Mar 200-110양질의 수익: GLOW 은(는) 현재 수익성이 없습니다.이익 마진 증가: GLOW는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: GLOW는 수익성이 없지만 지난 5년 동안 연평균 49.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 GLOW의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: GLOW은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(233.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: GLOW는 현재 수익성이 없으므로 자본 수익률이 음수(-16.56%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/07 18:46종가2026/08/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Glow Lifetech Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 26First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$643.5k (up 35% from 1Q 2025). Net loss: CA$58.9k (loss narrowed 60% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 08Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.03 loss in FY 2024)Full year 2025 results: CA$0.004 loss per share (improved from CA$0.03 loss in FY 2024). Revenue: CA$2.05m (up 146% from FY 2024). Net loss: CA$617.9k (loss narrowed 77% from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$630.8k (up 178% from 3Q 2024). Net loss: CA$106.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 28Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2024)Second quarter 2025 results: CA$0.002 loss per share. Revenue: CA$436.3k (up 186% from 2Q 2024). Net loss: CA$368.6k (loss widened 42% from 2Q 2024).
Reported Earnings • May 07Full year 2024 earnings released: CA$0.03 loss per share (vs CA$0.029 loss in FY 2023)Full year 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.029 loss in FY 2023). Revenue: CA$836.2k (up CA$792.3k from FY 2023). Net loss: CA$2.66m (loss widened 62% from FY 2023). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • May 26First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$643.5k (up 35% from 1Q 2025). Net loss: CA$58.9k (loss narrowed 60% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$9.62m market cap, or US$7.06m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$2.1m revenue, or US$1.5m).
Reported Earnings • Apr 08Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.03 loss in FY 2024)Full year 2025 results: CA$0.004 loss per share (improved from CA$0.03 loss in FY 2024). Revenue: CA$2.05m (up 146% from FY 2024). Net loss: CA$617.9k (loss narrowed 77% from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Recent Insider Transactions Derivative • Mar 29CEO & Director exercised options to buy CA$66k worth of stock.On the 23rd of March, Roberto Carducci exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$60k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since June 2025, Roberto's direct individual holding has increased from 6.88m shares to 8.08m. Company insiders have collectively bought CA$141k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions Derivative • Mar 21CFO & Corporate Secretary exercised options to buy CA$66k worth of stock.On the 17th of March, Joshua Bald exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$66k. This transaction amounted to 56% of their direct individual holding at the time of the trade. Since June 2025, Joshua's direct individual holding has increased from 1.66m shares to 2.34m. This was the only transaction from an insider over the last 12 months.
공고 • Jan 07Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on MendoGlow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation.
Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$630.8k (up 178% from 3Q 2024). Net loss: CA$106.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
New Risk • Oct 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (CA$8.57m market cap, or US$6.11m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$1.5m revenue, or US$1.0m).
Reported Earnings • Aug 28Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2024)Second quarter 2025 results: CA$0.002 loss per share. Revenue: CA$436.3k (up 186% from 2Q 2024). Net loss: CA$368.6k (loss widened 42% from 2Q 2024).
공고 • Jun 23Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025.
공고 • Jun 03Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of DirectorsGlow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025.
Reported Earnings • May 07Full year 2024 earnings released: CA$0.03 loss per share (vs CA$0.029 loss in FY 2023)Full year 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.029 loss in FY 2023). Revenue: CA$836.2k (up CA$792.3k from FY 2023). Net loss: CA$2.66m (loss widened 62% from FY 2023). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공고 • Jan 29Glow Lifetech Corp. Announces Executive and Board ChangesGlow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary.
공고 • Nov 06Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in fundingGlow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws
New Risk • Sep 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (91% average weekly change). Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (CA$6.68m market cap, or US$4.95m).
공고 • Sep 25Glow Lifetech Corp. announced that it has received CAD 1.2 million in fundingOn September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering.
공고 • Aug 14Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in fundingGlow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
Board Change • Aug 07Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 21Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). ,CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Apr 17Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in fundingGlow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (42% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (CA$1.84m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding).
공고 • Dec 17Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in fundingGlow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
공고 • Sep 08Glow Lifetech Corp. Appoints Daniel Proska to Its Board of DirectorsGlow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023.
공고 • Jul 07Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder TechnologyGlow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products.
공고 • Dec 09Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Nov 03Glow Lifetech Corp. Completes Development of Proprietary MyCell Liquid Cannabis Ingredients; Advances Plans to Launch in Canadian MarketGlow LifeTech Corp. announced the completion of development of its proprietary MyCell® liquid cannabis ingredients, including THC and CBD. The Company now plans for commercialization in the Canadian market, given product readiness. The successful development of MyCell® liquid water-soluble THC and CBD ingredients allows the Company to immediately progress towards scaling-up production and making preparations for sellinginto the well-established market for THC and CBD products in Canada, as the first step in its global commercial strategy. As many cannabis industry players currently struggle with low-margin, commoditized product offerings, Glow has always maintained a long-term focus on delivering differentiated, value-added products and building a platform for high-margin growth. With its portfolio of high-performance, technology-driven products, the Company is well-positioned to capitalize on the growing industry-wide evolution towards high-value, science-based products. Glow's MyCell® Technology is a cutting-edge delivery system that optimizes the absorption, bioavailability and effectiveness of several verticals of natural active compounds including cannabinoids, vitamins, and botanicals, using only 100% natural components. It transforms poorly absorbed natural compounds, such as THC and CBD, into water-soluble compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its flexible technology platform and robust portfolio of enhanced ingredients, Glow can power a variety of product formats including: droppers, sprays, beverages, gummies, foods, topicals, and more. The Company has prudently built an efficient, asset-light cannabis production operation with a factor-in-factory manufacturing partnership in Toronto, Canada, that is designed to scale and minimize costs. With the processing facility built and equipment commissioned in early 2022, it will house all of Glow's cannabis-related R&D activities, serving as the Company's cannabis production centre of excellence to develop technologies and products that can be scaled globally. This single licensed production location provides the Company the necessary production capacity to produce a diverse portfolio of cannabis products to service the Canadian market nationally, across both adult-use and medical cannabis markets.
공고 • Jul 19Glow Lifetech Reports Positive Preliminary Results from Clinical Study of Artemic Support(R) on Patients with Long Covid SyndromeGlow LifeTech Corp. reported positive preliminary results from a clinical study into the influence of ArtemiC Support® on patients with Post-Acute COVID Syndrome, also known as Long COVID. Long COVID refers to the ongoing health problems that people can experience four or more weeks after being infected with SARS-COV-2[2], the virus responsible for COVID-19. Long COVID is believed to affect more than 50% of all COVID-19 patients. The study, undertaken in conjunction with primary care clinicals in Barcelona, CAP Can Bou and Sardenya EAP Spain, was an open label, single arm study, consisting of six-weeks of treatment with ArtemiC Support®. The objectives of the study were to provide an initial assessment of the safety and efficacy of ArtemiC Support® in Long COVID patients. The clinical study was sponsored by Swiss PharmaCan AG and co-sponsored by Glow and MGC Pharmaceuticals Ltd. The study enrolled 150 patients suffering from Long COVID who were administered ArtemiC Support®, under the supervision of their doctor, with their progress being measured using a Post-COVID Functional Scale (PCFS) and symptoms on a 10-point Likert scale at 1, 2, 3 and 6 weeks after treatment initiation. Symptoms measured include: Dyspnea - shortness of breath Asthenia - abnormal physical weakness or lack of energy, Anosmia - loss of senses of smell, Ageusia - loss of sense of taste, Cough, Headache, Mental confusion. The results of the study demonstrated a statistically significant reduction in the severity of several Long COVID symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion over the course of the protocol. The graphs below show the Emmeans (Estimated Marginal Mean) observed results from data collected during the Artemic Support® Long COVID study: · Dyspnea: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 5), with a higher emmean indicating higher severity and a lower enmean indicating a lower severity. · Cough: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visits 4 & 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. · Asthenia: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. Headache: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower enmeans indicating a lower. Mental confusion: a significant difference was seen in reported symptom intensity (visit 1 to visit 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity.
공고 • Jul 09Glow Lifetech Corp. Provides an Update on Commercial Operations, Cannabis-Related Development Activities and Clinical Studies Related to Its Proprietary Mycell®-Enhanced ProductsGlow Lifetech Corp. provided an update on commercial operations, cannabis-related development activities and clinical studies related to its proprietary MyCell®-enhanced products. Glow is now focused on the final stages of development of proprietary CBD (cannabidiol) and THC1 (tetrahydrocannabinol) water-soluble ingredients in preparation for launch in Canada. With Glow's licensed cannabis processing space now built out and equipment successfully commissioned earlier this year, the company has been actively developing a diverse portfolio of high-bioavailability cannabis ingredients and new proprietary technologies to expand the Company's portfolio of solutions. The Company's MyCell® Technology is an advanced delivery system that transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high- absorption and precise dosing. Glow is engaged with a renowned branding firm and is in the late stages of establishing a refreshed brand identity that reflects the cutting-edge performance and quality of its technology and products. The Company is also pleased to report the completion of the recruitment phase of the ongoing clinical study on patients with long COVID syndrome, to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology.2 Glow's portfolio of high-performance water-soluble cannabis ingredient solutions will unlock a step- change in what's possible with cannabis-infused products, enabling partner brands to easily innovate and differentiate with high-value products that are more effective, fast-acting, consistent and deliver predictable dosing. The versatility of MyCell® enhanced concentrates allows them to power a variety of product formats including: droppers, beverages, foods, topicals, and capsules.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Dec 27Glow LifeTech Corp Announces Commencement of Clinical Study of Artemic Support Featuring Mycell Technology on Patients with Long COVIDGlow LifeTech Corp. announced that it is co-sponsoring a clinical study to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology, in patients with Long COVID syndrome. Post-acute COVID syndrome (PACS) or "Long COVID" presents itself as a wide range of ongoing symptoms patients can experience for four or more weeks after first being infected with SARS-COV-2[1]. Long Covid is estimated to affect approximately 10%-35% of all COVID patients[2], and the inflammatory response is generally thought to be fundamental to the persistence of symptoms. Therefore, the ability to reduce inflammation could improve patient outcomes, and this study is aimed at validating such a framework for Artemic Support®. Artemic Support® is a natural health product made from curcumin, boswellia and vitamin C designed to reduce inflammatory responses and is formulated with MyCell® Technology ingredients to increase bioavailability and deliver faster, more effective cellular absorption of natural active ingredients. This new innovation is the second product in the Company's Artemic product range to progress to the Clinical Trial phase to determine safety and efficacy against SARS2-COV-2 related diseases. In April 2020, the Company announced it submitted its first product, ArtemicTM Rescue, to Health Canada as a Natural Health Product following successful results from a Phase II Clinical Trial with patients diagnosed with moderate COVID-19.
공고 • Apr 29Glow Lifetech Corp. Submits Application to Health Canada to Obtain Product Licenses for Artemic™MGC Pharmaceuticals Ltd. announced that Glow LifeTech has submitted an application to Health Canada to obtain product licenses for ArtemiC™ as a Natural Health Product (NHP), per its CSE announcement on 27 April 2021. As announced on 15 December 2020, MGC Pharma released the results of a successful Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing for toxicity and mechanism of action. ArtemiC™ was submitted to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) on March 11, 2021. The application, which is currently under review by Health Canada, included ArtemiC™ supporting COVID-19 Phase II clinical trial results. Under Canadian regulations, all NHPs must obtain premarket approval by Health Canada to assure they are safe, effective and of high quality before being allowed to be sold in Canada. Once Health Canada makes this assessment, they are issued a National Product Number (NPN). Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Caribbean countries as a food supplement. ArtemiC™ is a clinically tested oral spray containing four natural active ingredients: Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses the MyCell™ delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC™ was a collaborative development effort between MGC Pharma, Swiss PharmaCan AG and Glow, and is manufactured by MGC Pharma.